Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04189094

Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC

Small Cell Lung Cancer Limited Stage Clinical Trial

Official title:
Chemoradiotherapy With or Without Sintilimab in Limited-stage Small Cell Lung Cancer: a Multicenter Prospective Randomized Phase II Trial

Clinical Trial Summary

The study is a prospective, multi-center, open-label, randomized, and controlled phase II clinical trial.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04189094
Study type Interventional
Source Zhejiang Cancer Hospital
Contact Ming Chen, MD. PhD.
Phone 86-571-88122199
Email chenming@zjcc.org.cn
Status Not yet recruiting
Phase Phase 2
Start date January 1, 2020
Completion date July 1, 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04882033 - Concurrent Chemoradiotherapy Combination With Anlotinib for Limited-stage Small Cell Lung Cancer Phase 1
Recruiting NCT04543890 - A Prospective Study Comparing Two Radiotherapy Dose/Fraction and Omitting CTVs of the Primary Tumor in Limited SCLC Phase 2
Completed NCT03059667 - Immunotherapy as Second-line in Patient With Small Cell Lung Cancer Phase 2
Completed NCT01797159 - Hippocampal Prophylactic Cranial Irradiation for Small Cell Lung Cancer N/A
Completed NCT03214003 - Twice-daily SIB Radiotherapy Versus Standard Radiotherapy for Patients With SCLC N/A
Recruiting NCT04418648 - Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy Phase 2
Recruiting NCT05651802 - PCI and Brain MRI Follow-up vs Brain MRI Follow-up Alone in Limited-stage SCLC Patients N/A
Recruiting NCT05945745 - Molecular Analysis and Treatment Options of SCLC
Recruiting NCT04602533 - Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN) Phase 2